 At this time, I would like to turn the call over to Barbara Ryan, Eloxx Investor Relations. Welcome and thank you for joining us this afternoon for a review of Eloxx Pharmaceuticals first quarter 2020 financial results and business update. Joining me this afternoon are Dr. Greg Williams, our Chief Executive Officer; Neil Belloff, our Chief Operating Officer and General Counsel; Dr. Tom Haverty, our Chief Medical Officer; Dr. Matthew Goddeeris, our Vice President of Research; and Stephen MacDonald, our Vice President of Finance and Accounting. 